Advertisement

Topics

Generic sofosbuvir and daclatasvir bioequivalent to originators

05:08 EDT 13 Jul 2018 | Generics and Biosimilars Initiative

With the aim of eliminating hepatitis C (HCV) by 2030, some originator pharmaceutical companies have granted voluntary licences to generics companies to mass produce the direct-acting antivirals (DAAs) sofosbuvir and daclatasvir at low cost. In order to achieve this, generics makers need to demonstrate bioequivalent pharmacokinetics for their DAAs, compared to the originators. Therefore, researchers carried out a study to determine whether generics of sofosbuvir and daclatasvir had bioequivalent pharmacokinetics to the originators [1].

Original Article: Generic sofosbuvir and daclatasvir bioequivalent to originators

NEXT ARTICLE

More From BioPortfolio on "Generic sofosbuvir and daclatasvir bioequivalent to originators"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...